Journal of Clinical Oncology
Articles in this Issue
Improving resident education in ambulatory oncology: A targeted needs assessment.
e21034 Background: In order to address disparities in cancer detection and outcomes, internal medicine physicians require strong foundations in evidence-b...
Machine learning–informed navigation of patients in persistent poverty zip codes to improve colorectal cancer screening: A prospective controlled study.
10539 Background: Colorectal cancer (CRC) screening remains suboptimal, particularly in racially diverse and low-income populations. Machine learning (ML)...
Treatment decision patterns post–enfortumab vedotin plus pembrolizumab in metastatic urothelial cancer.
e16562 Background: Enfortumab Vedotin plus Pembrolizumab (EV+P) is increasingly adopted as a first-line (1L) treatment for metastatic urothelial carcinoma...
A phase 2 study of the OX40 agonist BGB-A445, in combination with docetaxel or BGB-15025, an HPK1 inhibitor, in patients with NSCLC pretreated by anti-PD-(L)1 antibodies.
e14513 Background: OX40, an immune costimulatory receptor mainly expressed on activated T cells, plays a role in T cell survival, proliferation, and proin...
Safety and effectiveness of fuzuloparib in patients with ovarian cancer: A nationwide, multicenter, prospective real-world study.
5572 Background: Fuzuloparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, is approved in China for the treatment of platinum-sensitive recurrent (PSR...
A first-in-human phase I/II study of GFH375, a highly selective and potent oral KRAS G12D inhibitor in patients with KRAS G12D mutant advanced solid tumors.
3013 Background: Kirsten rat sarcoma (KRAS) G12D is one of the most prevalent RAS mutations in human cancers and suggests poor survival. GFH375 is an oral...
Clinical predictors of response to immunotherapy in patients with extensive-stage small cell lung cancer.
e20125 Background: The addition of immunotherapy represents a significant breakthrough in the treatment paradigm of extensive-stage small cell lung cancer...
Anlotinib in combination with penpulimab and chemotherapy as first-line treatment for extensive-stage small cell lung cancer: A single-arm, prospective clinical study.
e20136 Background: In recent years, the combination of immunotherapy and chemotherapy has emerged as a standard first-line treatment for extensive-stage s...
Comparing ERK signaling and tumor microenvironment in BRAF-altered gliomas.
2063 Background: Many patients with BRAF-altered glioma (V600E mutations, fusions) respond to BRAF inhibitors (BRAFi), but some—particularly those with hi...
Comprehensive characterization of interleukin-enhanced factor 2 (ILF2) in triple-negative breast cancer (TNBC).
1114 Background: While treatment and management of TNBC has improved, there is a need for novel prognostic biomarkers to better inform outcomes and guide...
Real-world social determinants of health (SDOH) and outcomes of early-onset colorectal cancer (EO-CRC): An analysis of a large, nationally representative US community oncology network.
11005 Background: The rise of EO-CRC in individuals under the age of 50 presents a major public health challenge, as these patients may encounter unique b...
Diagnostic accuracy of machine learning models in glioma classification: A meta-analysis.
2079 Background: Machine learning (ML) is promising in IDH-based glioma classification using magnetic resonance imaging (MRI), but variability in methods...
Full-coverage therapy for converting unresectable advanced hepatocellular carcinoma.
e16238 Background: Unresectable advanced HCC remains a major clinical challenge, with limited treatment options and suboptimal outcomes. Achieving tumor c...
Association between epigenetic clocks and chemotoxicity in older adults with early breast cancer.
12135 Background: Epigenetic clocks are blood-based biomarkers developed to predict biological age and mortality risk from DNA methylation data. Here, we...
Trends in mortality due to myelodysplastic syndromes from 1999 to 2020: A CDC WONDER analysis.
e22568 Background: Myelodysplastic syndromes (MDS) are a group of clonal hematopoietic disorders with ineffective blood cell production causing cytopenias...
Quality of life among oncology patients with distinct spiritual well-being profiles.
12102 Background: Individuals undergoing treatment for cancer experience multiple symptoms moderated by stress/resilience that impact quality of life (QOL...
Phase 2, multicenter study of frontline maintenance therapy with lifileucel plus pembrolizumab in advanced non-small cell lung cancer.
TPS8659 Background: Tumor-infiltrating lymphocyte (TIL) therapy with lifileucel plus pembrolizumab (pembro) demonstrated durable and deepening responses w...
Efficacy and safety of dalpiciclib plus toremifene in advanced HR-positive HER2-negative breast cancer as first-line treatment: A multicenter, single-arm phase II trial.
e13062 Background: Dalpiciclib is a CDK4/6 inhibitor approved to treat metastatic hormone receptor-positive (HR+) breast cancer (mBC) in combination with...
US population-level costs and cost-savings associated with long-term follow-up (LTFU) screening for survivors of childhood cancer.
10059 Background: Children’s Oncology Group’s (COG) LTFU Guideline adherence is poor. We evaluated the impact of universal payer coverage on patient costs...
Real-life comparison between immunotherapy and conventional chemotherapy in patients with advanced anal cancer after first-line treatment.
e15501 Background: Phase II study have suggested potential benefits of immunotherapy for selected populations based on specific biomarkers in first line t...
Survival outcomes of patients with mNSGCTs with and without teratoma in the primary tumor: An international retrospective study.
5036 Background: Recent studies have reported conflicting findings on the outcomes of patients with metastatic nonseminomatous germ cell tumors (mNSGCT) a...
Clinicopathological features and survival outcomes in women with endometrial neuroendocrine tumors.
5604 Background: Endometrial neuroendocrine tumors (ENET) are rare, representing about 0.8% of endometrial cancers. Due to their aggressive nature, they a...
Trastuzumab deruxtecan (T-DXd) in patients (Pts) with HR-negative HER2-low metastatic breast cancer (mBC): A real-world experience.
e13127 Background: T-DXd was approved for the treatment of pts with human epidermal growth factor receptor 2 (HER2)-low mBC based on results from the DEST...
Camrelizumab combined with rivoceranib and TACE in the perioperative treatment of hepatocellular carcinoma: A randomized, open-label multicenter trial.
e16279 Background: The high recurrence rate following resection presents a significant challenge to the survival of patients with resectable hepatocellula...
Phase III randomized placebo-controlled trial on repurposing olanzapine for prevention of radiotherapy-induced nausea and vomiting (RINV): CTRI/2022/01/039723.
12001 Background: Prospective placebo controlled randomized study with or without olanzapine, to evaluate its role in reducing RINV in abdominal-pelvic ra...